Survival probabilities*
| . | Eligible population (n = 75) . | MR (n = 44) . | ASCT (n = 22)† . |
|---|---|---|---|
| PFS (95% CI) | |||
| 2 years | 0.76 (0.66-0.87) | 0.79 (0.67-0.92) | 0.76 (0.58-1.00) |
| 3 years | 0.72 (0.62-0.84) | 0.67 (0.52-0.85) | – |
| 4 years | 0.46 (0.31-0.69) | 0.59 (0.42-0.83) | – |
| OS (95% CI) | |||
| 2 years | 0.95 (0.90-1.00) | 0.93 (0.86-1.00) | 1.00 (1.00-1) |
| 3 years | 0.88 (0.81-0.96) | 0.91 (0.83-1.00) | 0.96 (0.87-1) |
| 4 years | 0.84 (0.76-0.93) | 0.86 (0.77-0.97) | 0.91 (0.79-1) |
| . | Eligible population (n = 75) . | MR (n = 44) . | ASCT (n = 22)† . |
|---|---|---|---|
| PFS (95% CI) | |||
| 2 years | 0.76 (0.66-0.87) | 0.79 (0.67-0.92) | 0.76 (0.58-1.00) |
| 3 years | 0.72 (0.62-0.84) | 0.67 (0.52-0.85) | – |
| 4 years | 0.46 (0.31-0.69) | 0.59 (0.42-0.83) | – |
| OS (95% CI) | |||
| 2 years | 0.95 (0.90-1.00) | 0.93 (0.86-1.00) | 1.00 (1.00-1) |
| 3 years | 0.88 (0.81-0.96) | 0.91 (0.83-1.00) | 0.96 (0.87-1) |
| 4 years | 0.84 (0.76-0.93) | 0.86 (0.77-0.97) | 0.91 (0.79-1) |
The PFS and OS in the entire population were calculated from study entry, whereas the PFS and OS for the subgroups of patients receiving MR or ASCT after VcR-CVAD induction were calculated from the start of MR or ASCT.
All patients in the ASCT arm had either progressed, died, or were censored within 2 years posttransplant; therefore, the 3- and 4-year PFS cannot be estimated.